NEWS & EVENTS
PRESS RELEASES 2007
ELUSYS SPONSORS PREMIER BIODEFENSE CONFERENCE
Pine Brook, NJ – May 22, 2007 – Elusys Therapeutics, Inc. (Elusys), a privately-held
biopharmaceutical company developing antibody based therapies for the treatment of life threatening infectious diseases announced that it is a sponsor of a national conference focusing on government and industry strategies for accelerating U.S. biodefense efforts.
The 5th Annual Biodefense Vaccines & Therapeutics conference (June 4-6, 2007 -Washington, DC) addresses policy, funding and development efforts and issues. The conference brings together the Nation's leading pharmaceutical and biotechnology companies, institutes, universities, government officials and other thought leaders to review the need for biodefense vaccines, therapeutics and other medical countermeasures.
Anthim™ Background
In March 2007, Elusys announced that Anthim™, the company's anthrax antibody therapeutic, was selected to R&D Directions' list of "100 Great Investigational Drugs."
Anthim is high affinity monoclonal antibody that targets the protective antigen component of anthrax infection, blocking the bacteria's ability to form deadly toxins. It is being developed for prophylaxis and post-exposure treatment of inhalation anthrax. Anthim has been granted Fast Track status and Orphan Drug Designation by the FDA and is being developed under the FDA Animal Rule, a regulatory process specifically designed for the development of medical countermeasures to bioterror threats.
For more information about Elusys or Anthim please visit www.elusys.com. For more information about the conference please visit www.infocastinc.com/biovac07.html.
About Elusys
Elusys Therapeutics is a privately-held biopharmaceutical company focused on the development of targeted anti-infective therapeutics using its proprietary HP Antibodies™ for the treatment of lifethreatening infectious diseases. Current venture investors include Essex Woodlands Health Ventures LLC, Invesco Private Capital, Crescendo Ventures, MedImmune Ventures and Pfizer.